Lectin complement pathway initiators after subarachnoid hemorrhage - an observational study.

It was already known that the complement system plays a role in immune responses and inflammation in the central nervous system. However, the specific involvement of lectin complement pathway initiators in subarachnoid hemorrhage remained unclear. Prior research had shown that these proteins can activate immune cascades in response to pathogens or tissue damage. No prior work had resolved how these proteins behave in cerebrospinal fluid or plasma after SAH. This gap motivated the need to track their levels over time and assess their clinical relevance. Researchers had not yet determined if these proteins could serve as biomarkers for delayed cerebral ischemia or functional outcomes. The uncertainty around their role in SAH outcomes drove the design of this observational study. No prior study had compared these proteins in SAH patients and healthy controls across multiple time points. This study aimed to clarify the temporal dynamics and clinical associations of LCP initiators in SAH.

This study aimed to examine the time-course of lectin complement pathway initiators in cerebrospinal fluid and plasma after subarachnoid hemorrhage. The researchers wanted to determine if these proteins could serve as indicators of delayed cerebral ischemia or functional outcomes. They focused on ficolin-1, ficolin-2, ficolin-3, and mannose-binding lectin. The motivation was to assess the potential clinical utility of these proteins in monitoring SAH patients. The study also aimed to compare levels in SAH patients with those in healthy controls. Researchers were interested in whether these proteins showed distinct patterns in patients who developed DCI. The goal was to identify any associations between LCP initiators and poor functional outcomes. This observational approach allowed for the collection of daily samples over a nine-day period.

The study collected daily cerebrospinal fluid and plasma samples from SAH patients for up to nine days after admission. Researchers measured concentrations of ficolin-1, ficolin-2, ficolin-3, and MBL using immunoassays. A total of 399 CSF and 358 plasma samples were analyzed from 63 and 50 patients, respectively. Twelve patients undergoing spinal anesthesia and 12 healthy blood donors served as controls. The researchers recorded the development of delayed cerebral ischemia during hospitalization. Functional outcomes were assessed using the modified Rankin Scale at three months. Statistical adjustments were made for age, sex, clinical severity, and CT findings. The study was registered at clinicaltrials.gov with identifiers NCT01791257 and NCT02320539.

On admission, CSF levels of all LCP initiators were higher in SAH patients compared to healthy controls. Ficolin-1 showed a biphasic pattern, with initial high levels followed by a decline. In univariate analysis, higher CSF levels of all four proteins were linked to worse functional outcomes. After adjusting for confounders, ficolin-1 and MBL remained significantly associated with poor outcomes. Patients with DCI had slightly higher increases in ficolin-1 and MBL over time. However, these associations did not survive adjustment for multiple testing. Plasma levels of ficolin-1 and ficolin-3 were consistently lower in SAH patients than in controls. No significant associations were found between plasma LCP initiators and DCI or functional outcomes.

The authors reported that SAH patients had elevated CSF levels of ficolin-1, ficolin-2, ficolin-3, and MBL. They noted that higher CSF levels of ficolin-1 and MBL were linked to worse functional outcomes in multivariate analysis. The biphasic pattern of ficolin-1 suggests a dynamic response to SAH. However, the study did not confirm a strong link between LCP initiators and DCI. The researchers emphasized that these findings were based on a retrospective analysis of prospectively collected samples. They proposed that CSF LCP initiators may serve as potential biomarkers for SAH outcomes. The authors suggested that further research is needed to validate these associations. The study highlights the need to explore the role of the lectin pathway in SAH pathophysiology.